Home > Publications database > Lung cancer mortality reduction by LDCT screening - results from the randomised German LUSI trial. > print

001     143926
005     20240229123017.0
024 7 _ |a 10.1002/ijc.32486
|2 doi
024 7 _ |a pmid:31162856
|2 pmid
024 7 _ |a 0020-7136
|2 ISSN
024 7 _ |a 1097-0215
|2 ISSN
024 7 _ |a altmetric:61601284
|2 altmetric
037 _ _ |a DKFZ-2019-01484
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Becker, Nikolaus
|0 P:(DE-He78)1573258b58c33f1922ca9719d0c8c4ab
|b 0
|e First author
|u dkfz
245 _ _ |a Lung cancer mortality reduction by LDCT screening - results from the randomised German LUSI trial.
260 _ _ |a Bognor Regis
|c 2020
|b Wiley-Liss
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1601381501_26602
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2020 Mar 15;146(6):1503-1513 #EA:C020#LA:E010#
520 _ _ |a In 2011, the US National Lung Cancer Screening Trial (NLST) reported a 20% reduction of lung cancer mortality after regular screening by low-dose computed tomography (LDCT), as compared to X-ray screening. The introduction of lung cancer screening programs in Europe awaits confirmation of these first findings from European trials that started in parallel with the NLST. The German Lung cancer Screening Intervention ('LUSI') is a randomized trial among 4,052 long-term smokers, 50-69 years of age, recruited from the general population, comparing 5 annual rounds of LDCT screening (screening arm; n=2,029 participants) with a control arm (n=2,023) followed by annual postal questionnaire inquiries. Data on lung cancer incidence and mortality and vital status were collected from hospitals or office-based physicians, cancer registries, population registers and health offices. Over an average observation time of 8.8 years after randomization, the hazard ratio for lung cancer mortality was 0.74 [95%CI: 0.46 - 1.19; p=0.21] among men and women combined. Modelling by sex, however showed a statistically significant reduction in lung cancer mortality among women (HR=0.31 [95%CI: 0.10 - 0.96], p=0.04), but not among men (HR=0.94 [95%CI: 0.54 - 1.61], p=0.81) screened by LDCT (pheterogeneity = 0.09). Findings from LUSI are in line with those from other trials, including NLST, that suggest a stronger reduction of lung cancer mortality after LDCT screening among women as compared to men. This heterogeneity could be the result of different relative counts of lung tumor sub-types occurring in men and women. This article is protected by copyright. All rights reserved.
536 _ _ |a 315 - Imaging and radiooncology (POF3-315)
|0 G:(DE-HGF)POF3-315
|c POF3-315
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Motsch, Erna
|0 P:(DE-He78)474d6825dc4c767e7164354e6fe8c885
|b 1
|u dkfz
700 1 _ |a Trotter, Anke
|0 P:(DE-He78)8597d05ee46a87bec084908e653c08ef
|b 2
|u dkfz
700 1 _ |a Heussel, Claus P
|b 3
700 1 _ |a Dienemann, Hendrik
|b 4
700 1 _ |a Schnabel, Philipp A
|b 5
700 1 _ |a Kauczor, Hans-Ulrich
|b 6
700 1 _ |a González Maldonado, Sandra
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Miller, Anthony B
|b 8
700 1 _ |a Kaaks, Rudolf
|0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
|b 9
|u dkfz
700 1 _ |a Delorme, Stefan
|0 P:(DE-He78)3e76653311420a51a5faeb80363bd73e
|b 10
|e Last author
|u dkfz
773 _ _ |a 10.1002/ijc.32486
|g p. ijc.32486
|0 PERI:(DE-600)1474822-8
|n 6
|p 1503-1513
|t International journal of cancer
|v 146
|y 2020
|x 1097-0215
909 C O |p VDB
|o oai:inrepo02.dkfz.de:143926
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)1573258b58c33f1922ca9719d0c8c4ab
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)474d6825dc4c767e7164354e6fe8c885
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)8597d05ee46a87bec084908e653c08ef
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)3e76653311420a51a5faeb80363bd73e
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-315
|2 G:(DE-HGF)POF3-300
|v Imaging and radiooncology
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2020
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b INT J CANCER : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b INT J CANCER : 2017
920 2 _ |0 I:(DE-He78)E010-20160331
|k E010
|l E010 Radiologie
|x 0
920 0 _ |0 I:(DE-He78)C130-20160331
|k C130
|l Personalisierte Früherkennung des Prostatakarzinoms
|x 0
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
920 1 _ |0 I:(DE-He78)E010-20160331
|k E010
|l E010 Radiologie
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a I:(DE-He78)E010-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21